Carlotta Costa
Novartis (Switzerland)(CH)Harvard University(US)Washington University in St. Louis(US)Massachusetts General Hospital(US)Novartis Foundation(CH)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition(2016)978 cited
- → RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer(2015)626 cited
- → CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors(2014)432 cited
- → MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors(2012)358 cited
- → Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development(2008)263 cited
- → PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer(2019)260 cited